Ven­tyx un­veils pos­i­tive PhII ul­cer­a­tive col­i­tis da­ta but stock is down 20% due to com­pet­i­tive space

De­spite Ven­tyx Bio­sciences’ VTX002 meet­ing the pri­ma­ry end­point of a Phase II tri­al in mod­er­ate to se­vere ul­cer­a­tive col­i­tis, the com­pa­ny’s stocks have tanked ow­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER